Background: Controversy still exists as to the relative importance of menopausal status and lifestyle factors for the risk of coronary heart disease in women.
Objective: The purpose of this study was to assess the influence of body mass index (BMI), smoking,lipoprotein levels, surgically induced menopause, hormone replacement therapy (HRT), years since menopause, and age on hemostasis in apparently healthy postmenopausal women.
Methods: Lipoproteins (total cholesterol [TC], low-density lipoprotein cholesterol, high-density lipoprotein cholesterol [HDL-C], triglycerides [TG]), and hemostatic factors (fibrinogen, von Willebrand factor antigen [vWFag], coagulation factors VIIag [FVIlag] and VIIa [FVIIa], plasminogen activator inhibitor 1 [PAI-1]) were each measured once. A forward, stepwise, multiple regression analysis was used to assess variations in hemostatic parameters.
Results: A group of 292 healthy Stockholm women recruited from the census register participated in the Stockholm Female Coronary Risk Study as controls. Of these women, 260 participated in the present study. BMI, smoking, lipoprotein levels, surgically induced menopause, and years since menopause (1-5 y) were found to be associated with a 31% increase in fibrinogen levels. A 7% increase in FVIIa levels was attributed to TC, BMI, and HRT. Years since menopause (1-15 y), TG, TC, BMI, and HRT were associated with an increase of up to 26% in FVIIag levels. A 9% increase in vWFag correlated with HDL-C and years since menopause (1-10, 11-14, and > or =15 y). BMI and TG explained a 21% and 3% increase, respectively, in PAI-1 levels. Neither the use of HRT nor years since menopause had any influence on hemostasis.
Conclusion: BMI, high levels of TC and TG, and low HDL-C levels appear to be more important than hormonal status in their impact on hemostatic variables in healthy postmenopausal women.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1550-8579(05)80015-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-Aging Tests for Middle Aged Women.
J Menopausal Med
December 2024
Department of Obstetrics and Gynecology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
The interest in aging and anti-aging research has increased significantly in recent years, leading to rapid expansion in the anti-aging market. Aging is associated with gradual physiological changes and an elevated risk of age-related ailments, and is divided into three categories: usual aging, successful aging, and pathological aging. Each category is associated with distinct implications for health and well-being.
View Article and Find Full Text PDFManagement of Common Benign Gynecologic Diseases in Postmenopausal Women.
J Menopausal Med
December 2024
Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Yangsan, Korea.
This study investigated the impact of menopause on the progression and management of common benign gynecological conditions such as polycystic ovary syndrome, endometriosis, uterine fibroids, and adenomyosis. These conditions often present with menstruation-related symptoms such as irregular cycles, heavy bleeding, and pelvic pain. While these symptoms typically subside after menopause, the underlying pathology of such benign gynecological conditions may be differentially affected by the physiological changes associated with menopause, sometimes leading to exacerbation or additional management challenges.
View Article and Find Full Text PDFEffects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.
Clin Breast Cancer
December 2024
Sermonix Pharmaceuticals, Columbus, OH.
Background: Lasofoxifene, a novel endocrine therapy (ET), showed antitumor activity versus fulvestrant in women with ESR1-mutated, metastatic breast cancer (mBC) that progressed on prior ET (phase 2, ELAINE 1 study). We investigated changes in genitourinary syndrome of menopause (GSM) vulvar-vaginal symptoms with lasofoxifene and how patient/disease characteristics affect baseline vulvar-vaginal symptoms in ELAINE 1.
Methods: Women were randomized to oral lasofoxifene 5 mg/day or IM fulvestrant 500 mg (days 1, 15, and 29, then every 28 days) until disease progression/severe toxicity.
Exploring the Relationships between Sex Hormones and Abdominal Muscle Area and Radiodensity in Postmenopausal Women: Insights from the Multi-Ethnic Study of Atherosclerosis.
Maturitas
January 2025
General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
The relationships between sex hormone levels and muscle composition in postmenopausal women remain underexplored. To address this gap, we conducted a cross-sectional observational study utilizing data from the Multi-Ethnic Study of Atherosclerosis. Our analysis included 682 postmenopausal women aged 45-84 years with complete data, with a mean age of 63.
View Article and Find Full Text PDFUnraveling the controversy: exploring the link between sex hormones and skin cancers through a meta-analysis and systematic review.
Arch Dermatol Res
January 2025
Department of Plastic and Burn Surgery, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Wuhou District, Chengdu, 610041, Sichuan Province, P. R. China.
Skin cancers continue to present unresolved challenges, particularly regarding the association with sex hormones, which remains a topic of controversy. A systematic review is currently warranted to address these issues. To analyze if sex hormones result in a higher incidence of skin cancers (cutaneous melanoma, basal cell carcinoma, squamous cell carcinoma).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!